ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ARISE-3 Dry Eye Trial Does Not Meet Primary Outcome Measures
March 24, 2021RegeneRx Biopharmaceuticals announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome did not meet its primary outcome measures. -
RegeneRx Joint Venture Announces Neurotrophic Keratopathy Trial Results
May 20, 2020ReGenTree and RegeneRx Biopharmaceuticals announced the results of a randomized, double masked, placebo-controlled Phase 3 clinical trial (SEER-1) using RGN-259 for the treatment of neurotrophic keratopathy (NK). -
RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259
February 14, 2019RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration....
Pharma Sources Insight January 2025
